News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
ReNeuron Preliminary Results For The Year Ended 31 March 2006
June 28, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Significant progress with late pre-clinical development of lead ReN001 stroke therapy, including repeat efficacy and dose response data and completion of scale-up to full cGMP1 standard
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
MORE ON THIS TOPIC
Antibody-drug conjugate (ADC)
Roche Inks Another China ADC Pact With $1.5B Hansoh Bet
October 17, 2025
·
2 min read
·
Tristan Manalac
Collaboration
Kite Makes $1.5B+ Cell Therapy Pact With Pregene as Others Pull Back
October 17, 2025
·
2 min read
·
Tristan Manalac
Autoimmune disease
Sanofi Joins With EVOQ in $500M Autoimmune Alliance
October 16, 2025
·
2 min read
·
Tristan Manalac
Funding
Veradermics Gets $150M Series C To Advance Hair Regrowth Pill
October 16, 2025
·
2 min read
·
Tristan Manalac